eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | small cell carcinoma |
| Comorbidity | C0080032|malignant pleural effusion |
| Sentences | 8 |
| PubMedID- 23523589 | The diagnostic value of apolipoprotein e in malignant pleural effusion associated with non-small cell lung cancer. |
| PubMedID- 24049303 | The diagnosis of malignant pleural effusion with non-small cell carcinoma does not necessarily imply that patient has incurable disease. |
| PubMedID- 23925664 | Vascular endothelial growth factor (vegf) is involved in non-small cell lung cancer (nsclc) with malignant pleural effusion (mpe), but little is known regarding the efficacy of bevacizumab (bev) with carboplatin-paclitaxel (cp) for nsclc with mpe. |
| PubMedID- 20819493 | Objective: to compare the therapeutic effects of pleural perfusion of ndp and cddp in non-small cell lung cancer (nsclc) patients with malignant pleural effusion, their quality of life and toxic side effects. |
| PubMedID- 20207133 | A phase i clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. |
| PubMedID- 25764010 | Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. |
| PubMedID- 21625182 | Predictive value of f-18 fdg pet/ct for malignant pleural effusion in non-small cell lung cancer patients. |
| PubMedID- 23656925 | The question addressed was whether surgery could ever be justified in non-small cell lung cancer patients with an unexpected malignant pleural effusion at surgery. |
Page: 1